Jacques Sanschagrin v GlaxoSmithKline Inc.
Superior Court, district of Montreal, no 500-06-000479-093
On August 10, 2009, Petitioner Jacques Sanschagrin filed a motion for authorization to institute a class action against GlaxoSmithKline at the Superior Court of Québec.
On October 9, 2014, the Superior Court of Québec approved the out-of-court settlement reached by the parties on September 4, 2014.
Quebec residents who were prescribed and ingested the medication sold under the name of Requip prior to September 4, 2014, and who subsequently developed an impulse control disorder.
The deadline to file a claim form (Schedule A to the Settlement, available below) and the necessary supporting documentation, for gambling losses and/or life impacts sustained prior to August 10, 2009, is April 21, 2015.
For additional information, please consult the notice of Settlement approval and the Settlement Agreement.
If you wish to opt-out of the class action, you must do so before April 21, 2015. The steps relating to, and the effects of, opting-out are also indicated in the notice of Settlement approval.
Lauzon Bélanger Lespérance inc.
286 Saint-Paul Street West, suite 100
Montréal (Québec) H2Y 2A3
Counsel for Defendants
Borden Ladner Gervais
1000 de La Gauchetiere Street West, suite 900
Montréal (Québec) H3B 5H4
Telephone : 514.879.1212
Notice of Settlement approval
Judgment approving the Settlement Agreement (French version only)
Notice to members
Schedule A – Claim Form
Schedule B – Opt out Form
Schedule C – Letter to physician and certificate
Motion to institute a class action (French version only)